SEATTLE & SINGAPORE, September 27, 2023 Accelerator Life Science Partners (ALSP), an early-stage life science accelerator and investment firm that creates and builds next-generation biotechnology companies centered on innovative science, today announced the Series A financing of Automera, a new biotechnology company that focuses on the development of autophagy-targeting chimera small molecules (AUTACs). Augmented with quantum chemistry and artificial intelligence (AI) enabled drug discovery too
Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studiesCompany expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024SEATTLE (BUSINESS WIRE) KayoThera, Inc. (“KayoThera”), an early-stage th.
New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity FundingAdditional funding will support advancement of KayoThera’s development programs in diabetes and oncologySEATTLE (BUSINESS WIRE) KayoThera, Inc. (“KayoThera”), an.